Associated tags: Curie Institute (Paris), Doctor of Philosophy, LSP, Research, Pharmaceutical industry, Physician, Committee on European Affairs and Oversight of the European Funds, TVI, Immunity, Union, Gastroenterology, Cancer, Neurodegeneration, Patient, Neuroscience, Felice, BMS, Financial services, Vaccine, Lead, Fine chemical, Egle Therapeutics
Locations: MUNICH, AMSTERDAM, PARIS, SAINT-CLOUD, BELGIUM, BOSTON, FRANCE, EUROPE, ITALY, AUSTRIA, GERMANY
Retrieved on:
Wednesday, March 27, 2024
Science,
Stem Cells,
Biotechnology,
Research,
Pharmaceutical,
Oncology,
Health,
Clinical Trials,
Egle,
Natural science,
Leukemia,
Patient,
Cell biology,
CMC,
Head,
Doctor of Philosophy,
MD,
IND,
Clinical trial,
Investigational New Drug,
Therapy,
International school,
CSO,
Pharmaceutical industry Egle Therapeutics, a biotechnology company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, announced today the appointment of Monica Gostissa, PhD, as Chief Scientific Officer and Reno Winter, PhD, as Chief Technical Officer.
Key Points:
- Egle Therapeutics, a biotechnology company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, announced today the appointment of Monica Gostissa, PhD, as Chief Scientific Officer and Reno Winter, PhD, as Chief Technical Officer.
- “I'm excited to join Egle Therapeutics to help develop novel immunotherapies targeting T regulatory cells for oncology and autoimmune diseases.
- “I am happy to be part of Egle Therapeutics’ leadership team to contribute my expertise in CMC and beyond to the company’s mission.
- Dr. Winter is a trained biochemist and received his PhD in Natural Sciences from the Martin Luther University Halle-Wittenberg, Germany.
Biotechnology,
Health,
Other Health,
Radiology,
Pharmaceutical,
Stem Cells,
Oncology,
Other Science,
Research,
Medical Devices,
Infectious Diseases,
Genetics,
Science,
Clinical Trials,
Cloud,
Curie Institute (Paris),
Norwest Venture Partners,
Ipsen,
Organization,
Partnership,
SPAC,
Boehringer Ingelheim,
EFSI,
Degenerative disease,
European Commission Investment Plan for Europe,
Therapy,
Doctor of Philosophy,
Takeda Pharmaceutical Company,
Research,
Quality of life,
European Union,
View,
LP record,
List of life sciences,
INSERM,
LSP,
Lead,
Education,
Physician,
Committee on European Affairs and Oversight of the European Funds,
Industry,
Investment,
TVI,
Immunity,
CEO,
Growth,
Union,
Gastroenterology,
Institute,
Cancer,
Neurodegeneration,
Patient,
Neuroscience,
Felice,
BMS,
Pharmaceutical industry,
Vaccine,
Financial services,
Fine chemical,
Egle Therapeutics,
LSP,
Bpifrance – InnoBio 2,
Takeda Ventures Inc.,
Fund+,
Bioqube Ventures,
Institut Curie,
EGLE THERAPEUTICS,
LSP,
BPIFRANCE – INNOBIO 2,
TAKEDA VENTURES INC.,
FUND+,
BIOQUBE VENTURES,
INSTITUT CURIE The Series A was co-led by LSP and Bpifrance through their InnoBio 2 fund.
Key Points:
- The Series A was co-led by LSP and Bpifrance through their InnoBio 2 fund.
- The new capital will be used primarily to advance 2 leads assets into the clinic and further strengthen its internal drug pipeline.
- The investor syndicate will join the Egle Therapeutics Board which will consist of Felice Verduyn-van Weegen (LSP), Vincent Brichard (LSP), Jean-Francois Morin (Bpifrance InnoBio 2) and Sacha Mann (Takeda Ventures).
- Philippe Monteyne (Fund+), Jacques Mizrahi (Bioqube Ventures) and Elisa El Nouchi (Bpifrance InnoBio 2) will join as observers.
Retrieved on:
Thursday, November 26, 2020
Research,
Other Health,
Radiology,
Pharmaceutical,
Oncology,
Medical devices,
Infectious diseases,
Genetics,
Clinical trials,
Science,
Biotechnology,
Stem cells,
Health,
Branches of biology,
Regulatory T cell,
Companies,
Takeda Pharmaceutical Company,
Immunotherapy,
Clinical medicine Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing first-in class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases, today announces that it has achieved the first milestone in its strategic research alliance with Takeda Pharmaceutical Company Limited (Takeda).
Key Points:
- Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing first-in class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases, today announces that it has achieved the first milestone in its strategic research alliance with Takeda Pharmaceutical Company Limited (Takeda).
- In the course of the strategic research alliance that was announced in June 2020, Egle will validate novel tumor-infiltrating regulatory T-cell (Treg) targets against which Takeda will develop potential therapies.
- Egle has leveraged its unique bioinformatic and translational capabilities to successfully identify targets that will now be pursued under the terms of the alliance.
- We look forward to continuing our productive alliance with Takeda while pushing further our internal programs through the equity component of the alliance.
